推 LeoTis817 : 清冠一號有發論文啦，上次結論部分隨便掃了一下， 06/19 11:02
→ LeoTis817 : 說可以抑制S protein的結合、3CL蛋白酶活化、病毒 06/19 11:02
→ LeoTis817 : 複製，也可以抗發炎，抑制巨噬細胞IL-6、TNF-α 06/19 11:02
清冠一號的「論文」:
https://pubmed.ncbi.nlm.nih.gov/33249281/
Among 33 patients with confirmed COVID-19 admitted in two medical centers,
those (n = 12) who were older, sicker, with more co-existing conditions and
showing no improvement after 21 days of hospitalization were given NRICM101.
======
先不要說沒有雙盲或sample size少得可憐
這篇論文連treatment的primary endpoint是什麼都講不清楚
至於in vitro藥物機轉講得天花亂墜，就聽聽就好